source
- Regenxbio reports key gene therapy results, moves toward FDA accelerated clearance for DuchenneRegenxbio said its experimental gene therapy RGX-202 met the primary endpoint in a pivotal Duchenne muscular dystrophy trial, positioning the company to file for accelerated FDA clearance. In the…
- Regenxbio reports successful Duchenne gene therapy trial, clearing path to FDA filingRegenxbio announced that its experimental gene therapy for Duchenne muscular dystrophy met its primary endpoints in a recent clinical trial, producing sufficient levels of a truncated muscle protei…